{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:46:52Z","timestamp":1768434412266,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Lasers Surg Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>We evaluated if oxymetazoline therapy combined with 595\u2010nm pulsed dye laser (PDL) will be more beneficial than topical oxymetazoline alone for the improvement of erythematotelangiectatic rosacea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design\/Materials and Methods<\/jats:title><jats:p>This was a randomized, controlled, prospective clinical trial approved by an independent Institutional Review Board, which enrolled 34 patients with moderate to severe clinical erythema (CEA) into a two\u2010arm study of PDL with concomitant oxymetazoline cream (Arm 1) and oxymetazoline cream alone (Arm 2). Patients in Arm 1 were treated with 3 monthly laser sessions, which were started after 1 month of topical oxymetazoline cream. Thirty subjects continued with the study, and 25 subjects (Arm 1: 14, Arm 2: 11) completed the 6\u2010month follow\u2010up. With photographic comparison to baseline images, efficacy endpoints were based on clinical on\u2010site grading by both the investigator and the patient, using the grading tools for CEA, Global Aesthetic Improvement (GAI) assessment, vessel size improvement, and subject self\u2010assessment. These scales were assessed at baseline and\/or at each clinical follow\u2010up at 1, 2, 3, and 6 months. Subject satisfaction as well as post\u2010treatment immediate response and treatment\u2010associated pain scores were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Statistically significant improvement in CEA was seen in both arms at the 1\u2010, 2\u2010, and 3\u2010month post\u2010baseline visits (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Only Arm 1 presented statistically significant improvement in CEA (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) at 6 months post baseline with a mean score of 1.6 (almost clear\u2010mild) compared with 3.2 at baseline. Arm 1 showed significantly greater mean vessel size improvement at 3 months (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) and 6 months (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) post baseline compared to Arm 2. Significantly greater improvement (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) in the investigator GAI score was reported at the 2\u2010 and 6\u2010month follow\u2010ups compared with Arm 2. Subject GAI scores showed statistically significant greater improvement in Arm 1 compared with Arm 2 at both the 3\u2010 and 6\u2010month follow\u2010ups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). There were no complications or long\u2010term effects associated with PDL or topical oxymetazoline treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prospective trial verifies a safe, enhanced clinical outcome with the combination of PDL therapy and topical oxymetazoline for the treatment of erythematotelangiectatic rosacea patients. Lasers Surg. Med. \u00a9 2021 The Authors. <jats:italic>Lasers in Surgery and Medicine<\/jats:italic> published by Wiley Periodicals LLC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/lsm.23439","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T20:43:37Z","timestamp":1625690617000},"page":"1307-1315","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Randomized Controlled Pilot Study: Combined 595\u2010nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea"],"prefix":"10.1002","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0332-206X","authenticated-orcid":false,"given":"Pooja","family":"Sodha","sequence":"first","affiliation":[{"name":"Department of Dermatology George Washington University Washington 20037 District of Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-9857","authenticated-orcid":false,"given":"Amanda","family":"Suggs","sequence":"additional","affiliation":[{"name":"Department of Dermatology Duke University Health System Durham North Carolina 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish S.","family":"Munavalli","sequence":"additional","affiliation":[{"name":"Department of Dermatology Duke University Health System Durham North Carolina 27710"},{"name":"Dermatology, Laser &amp; Vein Specialists of the Carolinas Charlotte North Carolina 28207"},{"name":"Department of Dermatology Wake Forest University School of Medicine Winston\u2010Salem NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Dermatology and Laser Surgery Center Houston Texas 77030"},{"name":"Department of Dermatology University of Texas MD Anderson Cancer Center, University of Texas, McGovern Medical School Houston Texas"},{"name":"Department of Dermatology, Weill Cornell Medical College Houston Methodist Hospital  Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15122"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14764170902741311"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2009.01156.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.20621"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22819"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23253"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12048"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2007.33091.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31204"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10716.x"},{"issue":"11","key":"e_1_2_6_13_1","first-page":"1201","article-title":"Topical oxymetazoline cream 1.0% for persistent facial erythema associated with Rosacea: Pooled analysis of the two phase 3, 29\u2010day, randomized, controlled REVEAL trials","volume":"17","author":"Stein\u2010Gold L","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"e_1_2_6_14_1","first-page":"213","article-title":"Clinical pharmacokinetics of oxymetazoline cream following topical facial administration fo the treatment of erythema associated with rosacea","volume":"17","author":"Kuang AW","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23176"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.044"},{"issue":"3","key":"e_1_2_6_17_1","first-page":"308","article-title":"Phase 2 randomized, dose\u2010ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with Rosacea","volume":"17","author":"Dubois J","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2278"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22548"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22436"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1306018"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.20716"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.990412"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.170682"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23186"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.037"},{"key":"e_1_2_6_27_1","first-page":"S209","article-title":"Abstract of the alpha adrenergic receptor agonist oxymetazoline decreases erythema and inflammation in a UVB\u2010Induced Sunburn Model","volume":"133","author":"Tian M","year":"2013","journal-title":"J Invest Dermatol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.04.002"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20204"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22296"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13439"}],"container-title":["Lasers in Surgery and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lsm.23439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/lsm.23439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lsm.23439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:13:48Z","timestamp":1693228428000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lsm.23439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/lsm.23439"],"URL":"https:\/\/doi.org\/10.1002\/lsm.23439","archive":["Portico"],"relation":{},"ISSN":["0196-8092","1096-9101"],"issn-type":[{"value":"0196-8092","type":"print"},{"value":"1096-9101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"2021-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}